Symptomatic dementia therapy — acetylcholinesterase inhibitors and memantine — has been the mainstay of pharmacologic treatment for Alzheimer disease, Lewy body dementia, and Parkinson disease dementia for over two decades. While these drugs do not modify underlying pathology, they provide modest symptomatic benefit in cognition, function, and behavior that can be meaningful for individual patients and families. This page covers the symptomatic pharmacotherapy of dementia, with emphasis on the evidence base, practical use, and the integration with newer disease-modifying anti-amyloid therapies.

Acetylcholinesterase Inhibitors

Background: Cholinergic Hypothesis

  • AD pathology includes progressive degeneration of basal forebrain cholinergic neurons (nucleus basalis of Meynert).
  • Cortical acetylcholine deficit contributes to cognitive symptoms.
  • AChE inhibitors prolong synaptic acetylcholine action.

Donepezil (Aricept)

  • Selective AChE inhibitor.
  • Half-life ~70 hours; once-daily.
  • Doses: 5 mg → 10 mg → 23 mg (latter for severe AD).
  • Side effects: nausea, diarrhea, vivid dreams/nightmares, leg cramps, bradycardia (caution in conduction disease), syncope, insomnia (take morning if so), weight loss.
  • Most widely used; relatively well-tolerated.

Rivastigmine (Exelon)

  • AChE + butyrylcholinesterase inhibitor.
  • Oral: 1.5 → 6 mg BID; transdermal: 4.6 → 13.3 mg/24h.
  • Transdermal often better tolerated (less GI).
  • FDA-approved for PD dementia AND mild-moderate AD.
  • Particularly effective for DLB and PD dementia.
  • Side effects: GI more pronounced with oral.

Galantamine (Razadyne)

  • AChE inhibitor + allosteric nicotinic receptor modulator.
  • Twice-daily (immediate release) or once-daily (ER).
  • Doses: 4 → 12 mg BID (IR) or 8 → 24 mg daily (ER).
  • Side effects: nausea, dizziness, headache, weight loss.

Efficacy

  • Modest cognitive benefit on standardized cognitive scales.
  • ~6-12 months “delay” in cognitive decline at peak benefit.
  • Benefit declines over time but may persist for years.
  • Effect on activities of daily living and behavior often more meaningful.
  • Stop trial: if no benefit after 3-6 months, consider discontinuation.
  • Discontinuation can produce rapid decline (“withdrawal cognitive decline”) — careful timing.

Cardiac Considerations

  • AChE inhibitors increase vagal tone.
  • Bradycardia, AV block, syncope possible.
  • Caution with: sick sinus syndrome, advanced AV block.
  • Co-administration with beta-blockers, non-DHP CCBs may increase risk.

Specific Considerations

  • NSAIDs + AChE inhibitors: GI bleeding risk additive.
  • Pre-anesthesia: discuss with anesthesiologist (can affect succinylcholine, nondepolarizing blockers).
  • Surgical procedures: may need to hold; restart promptly post-op.

NMDA Receptor Antagonist

Memantine (Namenda)

  • Uncompetitive, voltage-dependent NMDA antagonist.
  • Theory: blocks pathological glutamate signaling while preserving physiological transmission.
  • 5 mg → 20 mg daily (titrate over 4 weeks).
  • ER formulation (28 mg daily).
  • Combination with donepezil (Namzaric) FDA-approved.
  • Indication: moderate to severe AD.
  • Side effects: dizziness, headache, confusion, constipation.
  • Generally well-tolerated; minimal cardiac effects (unlike AChE inhibitors).

Memantine Efficacy

  • Modest cognitive and functional benefit in moderate-severe AD.
  • Combination with AChE inhibitor: small additional benefit; FDA-approved combination.
  • Less evidence in mild AD.
  • Less effective in DLB and frontotemporal dementia.

Combination Therapy (AChE + Memantine)

  • Moderate to severe AD: combination beneficial.
  • Namzaric: combined donepezil + memantine ER.
  • Start: AChE inhibitor first; add memantine in moderate disease.
  • Discontinuation: stop memantine first if needed.

Behavioral and Psychological Symptoms of Dementia (BPSD)

Approach

  1. Identify triggers (pain, infection, medication, environmental).
  2. Non-pharmacologic first: behavioral interventions, music therapy, structured activities.
  3. Optimize cognitive medications.
  4. Pharmacologic ONLY when severe and impairing.

Agitation and Aggression

  • Brexpiprazole (Rexulti): FDA-approved 2023 for agitation in AD; balanced D2 partial agonism.
  • Citalopram: CitAD trial — effective for agitation; FDA dose limit (20 mg in elderly).
  • Atypical antipsychotics: risperidone, olanzapine, quetiapine — off-label; CMS black box (cerebrovascular events, increased mortality in dementia patients).
  • Trazodone: low-dose for agitation, sleep.
  • AVOID: haloperidol (sedating, EPS, mortality risk); benzodiazepines chronically (cognitive, falls).

Depression in Dementia

  • SSRIs first-line (sertraline, escitalopram, citalopram — note dose limit).
  • Mirtazapine: dual sleep + mood + appetite.
  • Avoid TCAs (anticholinergic).
  • Behavioral interventions critical.

Sleep Disturbance

  • Trazodone (low-dose).
  • Mirtazapine.
  • Melatonin.
  • Avoid benzodiazepines, zolpidem (paradoxical reactions, falls).
  • Address contributors: pain, sundowning patterns.

Anxiety

  • SSRIs first-line.
  • Buspirone alternative.
  • Benzodiazepines short-term only.

Apathy

  • Methylphenidate: limited evidence; some benefit in selected.
  • Donepezil/AChE may help indirectly.
  • Structured activities, engagement.

Drug Avoidance in Dementia

  • Anticholinergics: minimize; affect cognition acutely and chronically.
  • Benzodiazepines: chronic use; falls, cognitive worsening.
  • Z-drugs (zolpidem): paradoxical agitation, falls.
  • Opioids: confusion, constipation; use minimum effective dose.
  • Older first-generation antihistamines (diphenhydramine): anticholinergic burden.
  • Diphenhydramine for sleep: AVOID in elderly with dementia.

Practical Use and Monitoring

  • Start AChE inhibitor at diagnosis of mild-moderate AD.
  • Add memantine at moderate AD.
  • Continue if benefit (subjective family report).
  • Periodic reassessment for ongoing benefit.
  • Discontinue if no longer beneficial or burden of side effects.
  • Trial discontinuation in advanced disease — some patients tolerate; some decline.

Specific Dementia Considerations

Alzheimer Disease

  • AChE inhibitors: mild-moderate.
  • Memantine: moderate-severe; or combination.
  • Anti-amyloid mAbs: emerging; see dedicated page.

Dementia with Lewy Bodies

  • Rivastigmine: particularly effective.
  • Levodopa: may help parkinsonism; psychosis risk.
  • Hallucinations: pimavanserin or quetiapine.
  • RBD: clonazepam, melatonin.
  • AVOID typical antipsychotics (severe sensitivity).

Parkinson Disease Dementia

  • Rivastigmine: FDA-approved.
  • Manage psychosis carefully (above).

Frontotemporal Dementia

  • AChE inhibitors: limited benefit; can worsen behavioral symptoms.
  • Memantine: limited evidence.
  • SSRIs: helpful for some behavioral symptoms.
  • Trazodone: agitation, behavioral.
  • Manage symptoms; no disease-modifying therapy currently.

Vascular Dementia

  • AChE inhibitors: small benefit; not as effective as in AD.
  • Memantine: similar.
  • Primary: aggressive vascular risk factor management.

Mixed Dementia

  • Common (~50% of dementia in elderly).
  • Manage both: AChE/memantine + vascular risk factors.

🔍 Did You Know?

The 2023 FDA approval of brexpiprazole (Rexulti) for agitation associated with Alzheimer disease represents the first targeted treatment for this important neuropsychiatric symptom. For decades, agitation in AD had been managed with atypical antipsychotics off-label, accepting the FDA’s “black box” warning about increased mortality (~1.6× baseline) in dementia patients receiving these drugs. Brexpiprazole — a balanced D2 partial agonist and serotonin receptor modulator — demonstrated efficacy in two pivotal trials (3HC and 3HB) for AD-associated agitation, including aggression, restlessness, and irritability. The approval comes with a similar boxed warning about mortality, but represents a recognized therapeutic indication rather than off-label use, providing patients and clinicians with an evidence-supported option. The clinical implications: structured trials of brexpiprazole are now appropriate for moderate-to-severe agitation when non-pharmacologic interventions have been adequate, with realistic expectations about effect size. Other emerging approaches include CitAD-style use of citalopram (with dose limits in elderly), trazodone, melatonin, and structured behavioral interventions. The lesson generalizes: FDA approval for specific neuropsychiatric symptoms in dementia is shifting the standard of care from purely off-label management to evidence-based protocols. For practicing neurologists and dementia specialists, the conversation about agitation now includes brexpiprazole as a labeled option, accelerating its adoption. The long-term goal is more specific interventions (e.g., anti-inflammatory therapy, immune modulation) that address underlying neurochemistry rather than symptomatic treatment.

Pitfalls and Pearls

  • AChE inhibitors: donepezil, rivastigmine, galantamine; modest symptomatic benefit.
  • Rivastigmine: FDA-approved for PDD; particularly effective for DLB.
  • Memantine: NMDA antagonist; moderate-severe AD; well-tolerated.
  • Combination donepezil + memantine: moderate-severe AD.
  • AChE bradycardia: monitor; conduction disease concern.
  • Brexpiprazole: FDA-approved for AD agitation; D2 partial agonist.
  • CitAD: citalopram for agitation (FDA dose limit elderly).
  • Atypical antipsychotic: off-label; CMS mortality warning.
  • AVOID: anticholinergics, chronic benzodiazepines, zolpidem in elderly.
  • DLB sensitivity to neuroleptics: severe; AVOID typical antipsychotics.
  • RBD: clonazepam or melatonin.
  • FTD: AChE inhibitors may worsen behavior; SSRIs for behavioral.
  • Vascular dementia: aggressive vascular risk factor management.
  • Non-pharmacologic interventions first for behavioral symptoms.
  • Stop trial: 3-6 months if no benefit; rapid decline possible on discontinuation.

References

  1. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
  2. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893-903.
  3. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509-2518.
  4. Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia. JAMA Neurol. 2023;80(12):1307-1316.
  5. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease (CitAD). JAMA. 2014;311(7):682-691.
  6. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA. 2005;294(15):1934-1943.